Last Updated: May 25, 2026

Investigational Drug Information for Prexasertib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Prexasertib?

Prexasertib is an investigational drug.

There have been 19 clinical trials for Prexasertib. The most recent clinical trial was a Phase 2 trial, which was initiated on September 25th 2024.

The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Colorectal Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and National Cancer Institute (NCI).

There are ninety-one US patents protecting this investigational drug and one hundred and seventy-one international patents.

Recent Clinical Trials for Prexasertib
TitleSponsorPhase
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCCAcrivon TherapeuticsPHASE2
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCCH. Lee Moffitt Cancer Center and Research InstitutePHASE2
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial CarcinomaGOG FoundationPhase 1/Phase 2

See all Prexasertib clinical trials

Clinical Trial Summary for Prexasertib

Top disease conditions for Prexasertib
Top clinical trial sponsors for Prexasertib

See all Prexasertib clinical trials

US Patents for Prexasertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Prexasertib ⤷  Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Start Trial
Prexasertib ⤷  Start Trial 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate Eli Lilly and Company (Indianapolis, IN) ⤷  Start Trial
Prexasertib ⤷  Start Trial Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.